If you have been diagnosed with prostate cancer, you know how difficult it may be to treat and how few long-term results are. When treated with conventional oncology, stage four prostate cancer has a five-year survival rate that is notoriously poor. Patients diagnosed with prostate cancer early and surgically removed may still have increased PSA levels and micrometastasis, even though there is no visible tumor. On the other hand, many men with advanced prostate cancer do not experience remission despite conventional chemotherapy and testosterone-blocking drugs. There is no apparent reason why individuals with advanced or recurrent prostate cancer are less likely to react to traditional procedures than those with early stages of the illness.
Traditional medicine does not typically consider ongoing genetic mutation. Early therapies may be ineffective because they do not address crucial aspects of the disease, including tumor cells in the circulation. Because of prostate cancer’s sluggish growth rate, many individuals go into remission only to have their illness return a few years later. By the time men are diagnosed with stage four prostate cancer, traditional medical practice has frequently written them off. The usual procedures have been more concerned with short-term care of the disease than with long-term outcomes. Cutting-edge therapies from around the world to treat prostate cancer can be used in a way that gives patients long-lasting benefits regardless of their stage of prostate cancer.
Prostate Cancer Treatment Recommendations
Prostate cancer treatment recommendations are developed by the NCCN (National Comprehensive Cancer Network). They are used by nearly all major cancer centers. While these guidelines may be practical for people with early-stage prostate cancer, survival chances plummet for those with more aggressive or recurring forms of the disease. NCCN recommendations are based on the results of clinical studies that do not use customized and genetically-driven treatment and immunotherapy alternatives.
Finding and treating the contributing and causative variables that drive prostate cancer is essential for treating the illness. Obesity, poor nutrition, and exposure to the environment may be all variables that lead to prostate cancer. The number of studies linking BRCA genes to advanced prostate cancer has risen. It is predicted that males with a mutant BRCA 2 gene are seven times more likely than the general population to acquire prostate cancer. Some of the best cancer treatment centers in the country also treat the underlying causes of cancer.
Prostate Cancer Risk Factors
Age is the most significant risk factor for prostate cancer. After the age of 50, a man’s risk of acquiring prostate cancer skyrockets. Most occurrences occur in men over the age of 65.
A specific genetic (inherited) factor increases your risk of developing prostate cancer if it runs in your family. Our genetic counselors and testers can help you create a screening strategy to detect illness early by analyzing your risk level.
In addition, prostate cancer strikes African-American and Caribbean males with greater frequency. In these guys, prostate cancer is more common for unknown reasons.
By addressing the underlying causes of your prostate cancer, you can lessen the likelihood of a recurrence and make steady progress against it. There may be a critical element in prostate cancer treatment that is overlooked if genetic variables such as the BRCA genes and epigenetic-oncogene relationships are not addressed. Uromedix wants to manage your cancer’s underlying genetic and epigenetic causes, as well as some of the variables that may make it more difficult to cure.
Uromedix is Ready to Help
Providing urologic care and surgery, Uromedix is a medical “one-stop” center to successfully treat common male urological symptoms.
Contact us here.